Transformative Targeted Therapies
We are a clinical-stage oncology company integrating exacting science and a focus on patients. Our mission is to improve outcomes for cancer patients by advancing and expanding a portfolio of first-in-class and best-in-class therapeutic candidates.
Transformative Targeted Therapies
We are a clinical-stage oncology company integrating exacting science and a focus on patients. Our mission is to improve outcomes for cancer patients by advancing and expanding our portfolio of first-in-class and best-in-class therapeutic candidates.
Who We Are
We exist to discover and develop differentiated targeted cancer therapies that address high unmet need. We apply our expertise, pragmatism, and tenacity to tackle challenges in cancer therapy that others cannot. Our team members played key roles in the design, development, and commercialization of cutting-edge treatments, including ADCs that are now a standard-of-care for multiple cancer indications.
Pipeline
Our most advanced pipeline programs are varegacestat (formerly AL102), a late-clinical stage gamma secretase inhibitor for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which received IND clearance in Q1 2025. Our preclinical pipeline includes IM-1617, IM-1340, and IM-1335, all of which are ADCs pursuing undisclosed targets with expression in multiple solid tumors.
Science
Our preclinical discovery efforts center on ADCs. Our methodical approach allows us to pursue differentiated targets that have game-changing potential. Using a systematic, data-driven process, molecules are optimized for efficacy, tolerability, and clinical differentiation. This holistic approach optimizes each ADC component – antibody, linker, and payload – both in isolation and collectively.
Patients
Patients are our priority. We believe that patients deserve transformative therapies that deliver real benefit. This belief drives every part of our drug development process, from the design of molecules through the execution of clinical trials.
